Cohort profile: The North American AIDS cohort collaboration on research and design (NA-ACCORD)

International Journal of Epidemiology

Volumn 36, Issue 2, 2007, Pages 294-301

  Gange, Stephen J ^a   Kitahata, Mari M ^a   Saag, Michael S ^a   Bangsberg, David R ^a   Bosch, Ronald J ^a   Brooks, John T ^a   Calzavara, Liviana ^a   Deeks, Steven G ^a   Eron, Joseph J ^a   Gebo, Kelly A ^a   Gill, M John ^a   Haas, David W ^a   Hogg, Robert S ^a   Horberg, Michael A ^a   Jacobson, Lisa P ^a   Justice, Amy C ^a   Kirk, Gregory D ^a   Klein, Marina B ^a   Martin, Jeffrey N ^a   McKaig, Rosemary G ^a   Rodriguez, Benigno ^a   Rourke, Sean B ^a   Sterling, Timothy R ^a   Freeman, Aimee M ^a   Moore, Richard D ^a   more..

^a NA ACCORD Coordinating Center   (United States)

Author keywords

AIDS; Cohorts; Epidemiology; HIV

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COHORT ANALYSIS; EPIDEMIOLOGY; HUMAN IMMUNODEFICIENCY VIRUS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; EPIDEMIOLOGICAL DATA; ESOPHAGITIS; HEALTH CARE DELIVERY; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NORTH AMERICA; PRIORITY JOURNAL; PUBLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CANADA; COHORT STUDIES; FEMALE; HUMANS; MALE; RESEARCH; UNITED STATES;

NORTH AMERICA;

EID: 34447519058     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyl286     Document Type: Article

References (11)

1. Lau B, Gange SJ, Moore RD. The Clinical Cohort Study: Epidemiologic Issues. Provisionally accepted for publication, AIDS Research and Human Retrovirology.
2. Rodriguez B, Sethi AK, Cheruvu VK et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 2006;296:1498-506.
3. Anastos K, Gange SJ, Lau B et al. Association of race and gender with HTV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr 2000;24:218-26.
4. Chu H, Gange SJ, Yamashita TE et al. individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: An application using a Bayesian random change-point model. Am J Epidemiol 2005;162:787-97.
5. Schneider MF, Gange SJ, Williams CM et al. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS 2005;19:2009-18.
6. Morris J, Mehta S, Jacobson LP, Gange SJ. Injection drug use and patterns of highly active antiretroviral therapy use: An analysis of ALIVE, WIHS, and MACS cohorts. Submitted for publication.
7. Dean M, Carrington M, Winkler C et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996;273:1856-62.
8. Ledergerber B, Lundgren JD, Walker AS et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004;364:51-62.
9. Braitstein P, Brinkhof MW, Dabis F et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006;367:817-24.
10. May MT, Sterne JA, Costagliola D et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: A collaborative analysis. Lancet 2006; 368:451-8. Erratum in:1996;274:1069.
11. Braithwaite RS, Shechter S, Roberts MS et al. Explaining variability in the relationship between antiretioviral adherence and HIV mutation accumulation. J Antimicrob Chemother 2006;58 1036-43.